Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 May 14;128(10):1468-1486.
doi: 10.1161/CIRCRESAHA.121.318186. Epub 2021 May 13.

Pathophysiology and Therapeutic Approaches to Acute Decompensated Heart Failure

Joyce N Njoroge  1 , John R Teerlink  1   2
Affiliations
Review

Pathophysiology and Therapeutic Approaches to Acute Decompensated Heart Failure

Joyce N Njoroge et al. Circ Res. .

Abstract

Acute decompensated heart failure (ADHF) is one of the leading admission diagnoses worldwide, yet it is an entity with incompletely understood pathophysiology and limited therapeutic options. Patients admitted for ADHF have high in-hospital morbidity and mortality, as well as frequent rehospitalizations and subsequent cardiovascular death. This devastating clinical course is partly due to suboptimal medical management of ADHF with persistent congestion upon hospital discharge and inadequate predischarge initiation of life-saving guideline-directed therapies. While new drugs for the treatment of chronic HF continue to be approved, there has been no new therapy approved for ADHF in decades. This review will focus on the current limited understanding of ADHF pathophysiology, possible therapeutic targets, and current limitations in expanding available therapies in light of the unmet need among these high-risk patients.

Keywords: diagnosis; heart failure; hospitalization; morbidity; mortality; therapeutics.

PubMed Disclaimer

Figures

Figure.
Figure.
Complex interdependence of cardiac and multiorgan involvement contributing to acute decompensated heart failure (ADHF) development and medical therapy options. BNP/ANP indicates B-type/atrial natriuretic peptide; NIV, noninvasive ventilation; and RAAS, renin-angiotensin-aldosterone system.
See this image and copyright information in PMC

References

    1. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Jr, Colvin MM, Drazner MH, Filippatos GS, Fonarow GC, Givertz MM, et al. . 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: a Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017;136:e137–e161. doi: 10.1161/CIR.0000000000000509 - PubMed
    1. Verbrugge FH, Guazzi M, Testani JM, Borlaug BA. Altered hemodynamics and end-organ damage in heart failure: impact on the Lung and kidney. Circulation. 2020;142:998–1012. doi: 10.1161/CIRCULATIONAHA.119.045409 - PMC - PubMed
    1. O’Connor CM, Starling RC, Hernandez AF, Armstrong PW, Dickstein K, Hasselblad V, Heizer GM, Komajda M, Massie BM, McMurray JJ, et al. . Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med. 2011;365:32–43. doi: 10.1056/NEJMoa1100171 - PubMed
    1. Ross JS, Chen J, Lin Z, Bueno H, Curtis JP, Keenan PS, Normand SL, Schreiner G, Spertus JA, Vidán MT, et al. . Recent national trends in readmission rates after heart failure hospitalization. Circ Heart Fail. 2010;3:97–103. doi: 10.1161/CIRCHEARTFAILURE.109.885210 - PMC - PubMed
    1. Desai AS, Stevenson LW. Rehospitalization for heart failure: predict or prevent? Circulation. 2012;126:501–506. doi: 10.1161/CIRCULATIONAHA.112.125435 - PubMed

MeSH terms